Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Transcription

1 September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T RICHMOND, Calif., Sept. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating that a single infusion of Sangamo's novel ZFP Therapeutic, SB-728-T, resulted in sustained reduction and control of viral load (VL) in the absence of antiretroviral drugs (ART) in several subjects. In addition, a decrease in the size of the HIV reservoir, as demonstrated by measurement of HIV total DNA in peripheral blood mononuclear cells (PBMCs), was observed over a three year period in nine of nine subjects treated who remained on ART throughout the study. These decreases, in some cases a two to three-log reduction, are in remarkable contrast to the stable levels typically seen with ART treatment alone. The data were generated in clinical trials designed to evaluate safety and efficacy of SB- 728-T for the treatment of HIV/AIDS, and were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sunday, September 7, In an oral presentation, Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer, described data from two studies (SB Cohort 5 and SB ) designed to maximize the engraftment of ZFN modified CD4+ T-cells (SB-728-T) in which both copies of the CCR5 gene had been disrupted, making

2 these cells fully resistant to HIV infection. In total, across all trials that Sangamo has conducted, three CCR5 delta 32 heterozygote subjects have controlled VL to undetectable or < 1000 copies during a treatment interruption (TI) from ART, one for more than 59 weeks (to last measurement taken). In the 1101 study, two subjects have experienced a two-log decrease in viral load from peak (with Cytoxan conditioning of 1 gm/m 2 and 1.5 gm/m 2 ) which has been sustained in one subject for more than 39 weeks. Five subjects currently remain on extended TI (longer than the 16 week period defined in the protocol) with VLs <10,000 copies and CD4 counts of >500. "We have now demonstrated profound suppression of viral load in the blood and sustained functional control of the virus in multiple subjects treated with just a single infusion of SB-728-T," stated Dr. Ando. "In contrast, while there have been previous reports of functional control in two subjects who received bone marrow transplants from uninfected individuals, none of these individuals was able to maintain control of their viral load for longer than a few weeks in the absence of ART. Subjects on our trials have significantly surpassed that milestone. In addition, our data also suggest potential mechanisms for this immunologic control of the virus and the all important reservoir, which must be depleted in order to achieve lasting functional control of HIV in infected individuals." "Sangamo's data to date suggest that SB-728-T treatment can enable an individual's immune system to attack HIV infection from two directions: by controlling actively replicating virus in the blood and by reducing the latent HIV reservoir which turns over more slowly," said Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development. "Our aim is to provide a protected reservoir of immune memory cells to replenish the cells killed by HIV and to generate an effective immune response against the virus and opportunistic infections. SB-728-T treatment has resulted in an unprecedented and durable increase in CD4+ cells, which is likely to be primarily due to the expansion of protected CD4+ stem cell central memory' cells (T SCM ) which are selfrenewing stem-like cells. We postulate that protection of T SCM from infection provides two possible routes to limit, and ultimately control HIV in an infected individual. The protected CD4+ cells that T SCM generates can provide sustained anti-hiv immune helper function against infected cells, allowing functional control of virus in the blood and reservoir and, as these T SCM cannot be infected, their presence ultimately limits the ability of the reservoir to be replenished and maintained which may, over time, result in reservoir erosion." Some HIV-infected individuals, so-called 'elite controllers', can accomplish this without drug intervention. These individuals typically have low CCR5 expression and good antiviral CD8 responses, a characteristic shared by those SB-728-T treated subjects in which the greatest effects on the virus have been seen to date. With the recent acceptance of an IND for mrna delivery of ZFNs Sangamo is conducting an ongoing Phase 2 clinical trial, SB-728-mR-1401 (1401), designed to provide further evidence of functional control of HIV in additional subjects. The protocol incorporates a number of methods to increase the engraftment of CD4 T-cells that have undergone biallelic CCR5 gene modification, including certain criteria for subject selection, optimal Cytoxan preconditioning and a number of process improvements such as mrna delivery

3 of the ZFNs, which will allow the administration of multiple doses of the modified cells. In addition to a further three subjects treated at the optimal dose of Cytoxan using adenoviral delivery of ZFNs, the Company expects to enroll all nine subjects into the 1401 study by the end of "The data presented at ICAAC, continue to support our conviction that an immunologic approach to a functional cure of HIV is likely to be the most successful," added Dr. Nichol. "The SB-728-mR-1401 study combines our best understanding, from all of our clinical research, of the potential mechanism of this novel therapeutic and we believe that it will yield data that provide a clear path to pivotal studies." Sangamo's collaborators from the laboratory of Rafick-Pierre Sékaly, Ph.D., Co-Director & Chief Scientific Officer of the Vaccine & Gene Therapy Institute of Florida (VGTI Florida) also presented analyses of immunological data from SB-728-T-treated subjects (SB Cohorts 1-3). They demonstrated a large increase in CCR5-modified cells in the longlived T SCM compartment which may explain why CCR5-modified cells from a single infusion can be detected in all subjects over a prolonged period (more than 42 months). A median 0.9 log decrease in the size of the HIV reservoir at 36 months was observed in nine of nine subjects treated, as demonstrated by measurement of HIV total DNA in PBMCs. The decrease in reservoir showed a statistically significant correlation with an improvement in CD4 count. T SCM is thought to be the principal cell-type that comprises the HIV reservoir, which is a source of HIV that is maintained in infected individuals in the form of the HIV genome integrated into the CD4 T-cell's DNA. These HIV-carrying cells can be found throughout the body, in the blood, and in larger numbers in the lymph system. The reservoir cannot be diminished by ART which only inhibits the growth of actively replicating virus in the blood. When an HIV-infected individual with well-controlled virus stops taking ART, the reservoir serves as a source of HIV and the VL in the blood quickly rises before reaching a plateau at or around the viral set point. The data demonstrate that SB-728-T treatment is associated with reduction in both the VL and the levels of the reservoir. About SB-728-T Sangamo's drug, SB-728-T, is generated by ZFN-mediated modification of the gene encoding CCR5 in a patient's own T-cells. ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to the most common strain of HIV. Summary of Clinical Trial Design About SB Cohorts 1-3 The study was an open-label Phase 1 clinical trial to evaluate the safety and tolerability of single infusions of an escalating dose of an autologous (a patient's own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). The trial enrolled nine HIV-infected subjects (three cohorts of three subjects each) who have sub-optimal T-cell levels and no detectable viral load on long-term ART, so-called immunologic non-responders (INRs). Subjects remained on their existing antiviral therapy

4 while receiving treatment with SB-728-T. About SB Cohort 5 HIV-infected subjects heterozygous for the CCR5 delta-32 mutation (i.e. with one CCR5 gene that is naturally modified) who are currently on ART were enrolled and received a single intravenous infusion of SB-728-T (5 to 30 billion modified cells). Two months after SB-728-T treatment, subjects underwent a 16 week TI during which time their ART was discontinued. ART was reinstituted in subjects whose CD4 T-cell counts dropped, or whose HIV-RNA increased to pre-defined levels. At the end of the TI, subjects with a sustained detectable HIV viral load were reinstituted on ART. Subjects with a significantly reduced viral load were given the option of remaining off ART until HIV RNA levels rose significantly and/or their CD4 T-cell count dropped to pre-defined levels. A total of ten subjects were treated in this cohort. About SB Cohorts 1-5 SB is an open-label, dose escalation, multi-center study designed primarily to evaluate the safety and tolerability of escalating doses of cyclophosphamide (Cytoxan ) administered prior to SB-728-T infusion. Cytoxan is a drug that is used to transiently reduce the numbers of T-cells in the body, which then rapidly repopulate once the drug is discontinued, and it is into this "growth" environment that SB-728-T is infused. Such lymphodepletive treatment has been used to enhance engraftment of adoptively transferred T-cells in the treatment of cancer, and as therapy for numerous autoimmune diseases. The drug has been previously used in HIV-infected individuals and studies demonstrate that while the drug was transiently lymphodepleting, it did not significantly reduce total CD4 T-cell counts over the long term and was adequately tolerated. In addition to safety, the study is designed to evaluate the effect of escalating doses of Cytoxan on SB-728-T engraftment, the effect of SB-728-T treatment on viral load following ART interruption, the change in CD4+ T-cell counts in peripheral blood and the long-term persistence of SB-728-T. By protocol, HIV-infected subjects on ART were enrolled into five dose-escalating cohorts (three subjects/cohort), and received intravenous Cytoxan (200 mg, 500 mg/m 2, 1.0g/m 2, 1.5g/m 2 and 2.0g/m 2 ). In cohort two, an additional three subjects were evaluated on an improved anti-emetic protocol due to an adverse event of Grade 2 nausea observed in two subjects at that dose level. Within each cohort, treatment was staggered so that each subsequent subject was infused with Cytoxan two weeks after the preceding subject. One to three days after receiving Cytoxan, subjects were infused with SB-728-T (8.2 to 36.2 billion cells). Six weeks after SB-728-T infusion, subjects with CD4 cell counts 500 cells/mm 3 underwent a 16 week TI during which time their anti-retroviral therapy was discontinued. ART was reinstituted in subjects whose CD4 T-cell counts dropped and/or whose HIV-RNA increased to certain pre-defined levels. At the end of the TI, subjects with a sustained detectable viral load or reduced CD4 T-cell count were reinstituted on ART. However, subjects who had experienced a drop in viral load were given the option of remaining off ART until HIV-RNA levels rose and/or their CD4 T-cell count dropped below pre-defined levels. About SB-728-mR-1401

5 SB-728-mR-1401 is an open-label, multi-center study designed primarily to evaluate safety and tolerability and the effect of repeat doses of SB-728-T following optimal cyclophosphamide pre-conditioning, on engraftment, viral load and total CD4 counts in peripheral blood. The study will use a new improved process, using electroporation of mrna encoding the ZFNs, rather than an adenoviral vector to deliver the ZFNs to the isolated T-cells. This process enables repeat dosing of the product. Up to nine subjects will be enrolled into two cohorts. Each subject will receive a total of up to 40 billion ZFN modified T-cells. The first cohort will receive this dose divided into infusions of two equal doses of SB-728mR-T 14 days apart after a cyclophosphamide (1 g/m 2 ) preconditioning treatment two days prior to the first SB-728mR-T infusion, and the second cohort will receive three doses of cells. Dividing the total cell dose and administering sequentially in this manner is thought to maximize overall cell engraftment. Four weeks after the last SB- 728-mR infusion, subjects with CD4 cell counts 500 cells/mm 3 will undergo a 16 week TI during which time their anti-retroviral therapy will be discontinued. ART will be reinstituted in subjects whose CD4 T-cell counts drop and/or whose HIV-RNA increases to certain pre-defined levels. At the end of the TI, subjects with a sustained detectable viral load or reduced CD4 T-cell count will be reinstituted on ART. However, subjects who experience a drop in viral load will be given the option of remaining off ART until HIV-RNA levels rise and/or their CD4 T-cell count drops below pre-defined levels. About Sangamo Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures TM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and betathalassemia. It has also established strategic partnerships with companies in nontherapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at ZFP Therapeutic is a registered trademark of Sangamo BioSciences, Inc. This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references relating to research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform for the treatment of HIV/AIDS, including a potential functional cure for HIV/AIDS, the ability of a ZFP Therapeutic to control HIV infection, projected timing of release of SB-728-T clinical data, the expansion of clinical studies for HIV-infected individuals and the initiation of additional preclinical studies of ZFN-gene modification. Actual results may differ materially from these forwardlooking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will

6 validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo's public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forwardlooking information contained in this press release. Logo - SOURCE Sangamo BioSciences, Inc.